Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/35450
Title: Determinants of therapeutic lag in multiple sclerosis
Authors: Roos, I
Leray, E
Frascoli, F
Casey, R
Brown, JWL
Horakova, D
Havrdova, EK
Debouverie, M
Trojano, M
Patti, F
Izquierdo, G
Eichau, S
Edan, G
Prat, A
Girard, M
Duquette, P
Onofrj, M
Lugaresi, A
Grammond, P
Ciron, J
Ruet, A
Ozakbas, S
De Seze, J
Louapre, C
Zephir, H
Sa, MJ
Sola, P
Ferraro, D
Labauge, P
Defer, G
Bergamaschi, R
Lebrun-Frenay, C
Boz, C
Cartechini, E
Moreau, T
Laplaud, D
Lechner-Scott, J
Grand'Maison, F
Gerlach, O
Terzi, M
Granella, F
Alroughani, R
Iuliano, G
Van Pesch, V
VAN WIJMEERSCH, Bart 
La Spitaleri, D
Soysal, A
Berger, E.
Prevost, J
Aguera-Morales, E
McCombe, P
Trivino, TC
Clavelou, P
Pelletier, J
Turkoglu, R
Stankoff, B
Gout, O
Thouvenot, E
Heinzlef, O
Sidhom, Y
Gouider, R
Csepany, T
Bourre, B
Al Khedr, A
Casez, O
Cabre, P
Montcuquet, A
Wahab, A
Camdessanche, JP
Maurousset, A
Patry, I
Hankiewicz, K
Pottier, C
Maubeuge, N
Labeyrie, C
Nifle, C
Coles, A
Malpas, CB
Vukusic, S
Butzkueven, H
Kalincik, T
Issue Date: 2021
Publisher: SAGE PUBLICATIONS LTD
Source: Multiple sclerosis journal, experimental, translational and clinical, 27(12), p. 1838-1851
Abstract: Background: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups. Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation. Methods: Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an objective, validated method in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of clinical and demographic determinants. Results: High baseline disability scores, annualised relapse rate (ARR) > 1 and male sex were associated with longer therapeutic lag on disability progression in sufficiently populated groups: females with expanded disability status scale (EDSS) < 6 and ARR < 1 had mean lag of 26.6 weeks (95% CI = 18.2-34.9), males with EDSS < 6 and ARR < 1 31.0 weeks (95% CI = 25.3-36.8), females with EDSS < 6 and ARR > 1 44.8 weeks (95% CI = 24.5-65.1), and females with EDSS > 6 and ARR < 1 54.3 weeks (95% CI = 47.2-61.5). Conclusions: Pre-treatment EDSS and ARR are the most important determinants of therapeutic lag.
Keywords: Neurology;multiple sclerosis;observational study;therapeutic lag
Document URI: http://hdl.handle.net/1942/35450
e-ISSN: 2055-2173
DOI: 10.1177/1352458520981300
ISI #: 000677275500001
Rights: The Author(s), 2021. Article reuse guidelines: sagepub.com/journalspermissions
Category: A1
Type: Journal Contribution
Validations: ecoom 2022
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
roos-et-al-2021-determinants-of-therapeutic-lag-in-multiple-sclerosis.pdf
  Restricted Access
Published version1.32 MBAdobe PDFView/Open    Request a copy
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.